These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23248284)

  • 1. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
    Choi BD; Kuan CT; Cai M; Archer GE; Mitchell DA; Gedeon PC; Sanchez-Perez L; Pastan I; Bigner DD; Sampson JH
    Proc Natl Acad Sci U S A; 2013 Jan; 110(1):270-5. PubMed ID: 23248284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

  • 3. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
    Sternjak A; Lee F; Thomas O; Balazs M; Wahl J; Lorenczewski G; Ullrich I; Muenz M; Rattel B; Bailis JM; Friedrich M
    Mol Cancer Ther; 2021 May; 20(5):925-933. PubMed ID: 33632870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
    Sampson JH; Choi BD; Sanchez-Perez L; Suryadevara CM; Snyder DJ; Flores CT; Schmittling RJ; Nair SK; Reap EA; Norberg PK; Herndon JE; Kuan CT; Morgan RA; Rosenberg SA; Johnson LA
    Clin Cancer Res; 2014 Feb; 20(4):972-84. PubMed ID: 24352643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
    Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
    Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
    Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
    Choi BD; Suryadevara CM; Gedeon PC; Herndon JE; Sanchez-Perez L; Bigner DD; Sampson JH
    J Clin Neurosci; 2014 Jan; 21(1):189-90. PubMed ID: 24054399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
    Iurlaro R; Waldhauer I; Planas-Rigol E; Bonfill-Teixidor E; Arias A; Nicolini V; Freimoser-Grundschober A; Cuartas I; Martínez-Moreno A; Martínez-Ricarte F; Cordero E; Cicuendez M; Casalino S; Guardia-Reyes X; Fahrni L; Pöschinger T; Steinhart V; Richard M; Briner S; Mueller J; Osl F; Sam J; Colombetti S; Bacac M; Klein C; Pineda E; Reyes-Figueroa L; Di Somma A; González J; Nuciforo P; Carles J; Vieito M; Tabernero J; Umaña P; Seoane J
    Mol Cancer Ther; 2022 Oct; 21(10):1499-1509. PubMed ID: 35915983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
    Gedeon PC; Choi BD; Hodges TR; Mitchell DA; Bigner DD; Sampson JH
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):375-86. PubMed ID: 23927666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
    Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
    Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
    J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
    Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
    Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
    Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
    Heimberger AB; Archer GE; Crotty LE; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Neurosurgery; 2002 Jan; 50(1):158-64; discussion 164-6. PubMed ID: 11844246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.